MDT - Medtronic plc
Pre-market:
| Previous close | 83.76 |
| Open | 83.83 |
| Bid | 83.40 x 800 |
| Ask | 85.30 x 1400 |
| Day's range | 83.47 - 84.51 |
| 52-week range | 75.77 - 96.79 |
| Volume | |
| Avg. volume | 6,154,908 |
| Market cap | 111.429B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 29.28 |
| EPS (TTM) | 2.86 |
| Earnings date | 25 May 2023 |
| Forward dividend & yield | 2.76 (3.34%) |
| Ex-dividend date | 22 Jun 2023 |
| 1y target est | 91.23 |
Motley FoolCould AI Boost Growth at Medtronic?
Medtronic (NYSE: MDT) has grown revenue over the years thanks to its solid portfolio of medical devices. Medtronic has taken action, streamlining parts of the business and acquiring assets that could drive future revenue. Medtronic is incorporating AI into its devices more and more.
Motley FoolShould Income Investors Buy This Soon-to-Be Dividend King?
Imagine spending a lifetime building your investment portfolio only to worry about whether you will outlive the balance in your investment accounts. If you are exclusively buying growth stocks with the intent of eventually selling them off for capital gains to sustain your lifestyle, running out of money could be a possibility. Consider medical device maker Medtronic (NYSE: MDT).
Motley Fool3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
ZacksHere's Why You Should Retain Medtronic (MDT) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.
Motley Fool2 Newly Minted AI Stocks to Buy Right Now
Nowhere is this trend more evident than in the recent parabolic growth of graphics, computing, and networking solutions company Nvidia (NASDAQ: NVDA). Thanks to its central role as a pillar of global AI architecture, Nvidia has seen its market cap swell to nearly $1 trillion in 2023.
Motley Fool2 Healthcare AI Stocks to Buy on the Dip
Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).
Motley FoolIs It Too Late to Buy Medtronic's Stock?
History has shown that purchasing stocks in resilient companies that can weather market highs and lows is an effective long-term investment strategy. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, is one such company. For years, the company steadily increased its revenue and earnings, keeping its business stable.
CNW GroupMedtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 44th annual Goldman Sachs global healthcare conference on Monday, June 12, 2023.
ZacksMedtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Motley FoolWhy Medtronic Stock Sank Today
There was plenty of action in the company's shares in the wake of its divisive fourth-quarter results.
- Zacks
Medtronic (MDT) to Expand Diabetes Care With New Buyout
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
Motley FoolMedtronic (MDT) Q4 2023 Earnings Call Transcript
Joining me are Geoff Martha, Medtronic chairman and chief executive officer; and Karen Parkhill, Medtronic chief financial officer. Geoff and Karen will provide comments on the results of our fourth quarter and fiscal year 2023, which ended on April 28, 2023, and our outlook for fiscal year '24.
ZacksMedtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Motley FoolWhy Medtronic Stock Is Sinking Today
Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. Although Medtronic topped Wall Street's consensus forecasts for the three-month period, investors appear to be reacting negatively to the company's financial guidance. Management blamed a stubbornly strong dollar and persistently high inflation for this softer-than-expected financial guidance.
Yahoo Finance VideoMedtronic stock drops amid earnings beat, forecast missing expectations
Yahoo Finance Live discusses a drop in shares of Medtronic after the medical device maker issued a weaker than expected forecast.
ZacksCompared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended April 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksMedtronic (MDT) Beats Q4 Earnings and Revenue Estimates
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
- CNW Group
Medtronic to acquire wearable insulin patch maker EOFlow
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd. (KOSDAQ: 294090), manufacturer of the EOPatch® device — a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more i
ZacksMedtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Motley FoolMedtronic Stock: Bull vs. Bear
Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500. But is Medtronic a stock to consider buying right now? Here are the bull and bear cases for the medical device giant.
Motley FoolBetter Buy: Medtronic vs. Johnson & Johnson
Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.
- Zacks
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
Motley Fool2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade.
ZacksMedtronic's (MDT) Global Market Share Strong, FX Headwind Stays
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
ZacksMedtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
